CCL22 and hepatocellular carcinoma: This research group expanded on this finding by suggesting that blocking macrophage-derived chemokine (CCL22), which controls migration of Tregs via its receptor CCR4, may also be an immunotherapeutic strategy for HCC through a similar mechanism [117].